What should I do if my BMI is underweight?

See a clinician to rule out underlying causes (thyroid, GI, eating disorders, chronic disease). Track your intake for 1–2 weeks — many underweight adults eat less than they realize. Prioritize protein (1.2–1.6 g/kg of target weight), calorie-dense whole foods, and resistance training to build muscle. Address any eating disorders with professional support.

What should I do if my BMI is in the healthy range?

Maintain, do not optimize. Worrying about moving from 23.5 to 22.5 is rarely useful. Focus instead on regular movement, mostly whole-food nutrition, sleep, stress management, and routine checkups. BMI is a starting framework, not a chase target.

What should I do if my BMI is overweight?

Look first at waist circumference — above 40 in (102 cm) for men or 35 in (88 cm) for women is the more important signal. Then get a bloodwork panel (fasting glucose, HbA1c, lipids, blood pressure). Adopt sustainable nutrition and movement patterns rather than restrictive diets; sleep and stress matter more than people expect.

What should I do if my BMI is obese?

Work with a clinician. Establish a baseline with bloodwork, BP, and waist circumference. Discuss options ranging from lifestyle intervention (Class I) to medical therapy (Class II) to bariatric surgery (Class III or Class II with comorbidity). Significant weight loss is achievable with structured programs; you do not have to do it alone.

When should I see a clinician about my BMI?

In general, anytime your BMI is outside the healthy range and you want guidance. Specifically: BMI above 30 (or above 27 with a comorbidity), BMI below 18.5, sudden unintentional weight changes, or any concern about an underlying condition. A primary care visit is usually the right first step.

From BMI to Action – Next Steps After Checking Your Score

Moving Beyond BMI: Secondary Health Screenings

BMI is a first-pass screening tool — it tells you whether to look further, not what the problem is. Once BMI is established, clinical best practice dictates secondary anthropometric and biochemical testing to build a complete picture of metabolic health. The next practical steps are:

Waist circumference: The single most important supplement to BMI. A tape measure at the navel takes 30 seconds and provides a direct signal of visceral fat mass — the depot most closely linked to insulin resistance, fatty liver disease, and cardiovascular risk. WHO thresholds for elevated risk are 94 cm (37 in) for men and 80 cm (31.5 in) for women in European populations; 90 cm / 80 cm for Asian populations. A man with normal BMI but waist 105 cm has elevated metabolic risk that BMI alone would not flag.
Blood pressure: Hypertension frequently co-occurs with elevated BMI. Elevated BP (≥ 130/85 mmHg) adds a cardiovascular risk factor that modifies the urgency and approach to weight management. Target blood pressure and weight-loss interventions are often pursued simultaneously.
Fasting metabolic panel: Request from your clinician at your next physical. The essential markers are: fasting glucose or HbA1c (diabetes screening), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and liver enzymes (ALT, AST — liver enzymes elevated by fatty liver disease are common in visceral obesity). A single blood draw provides more metabolic information than a BMI number.
Comprehensive metabolic panel: For those with BMI in the obese range or with family history of metabolic disease, a full metabolic panel including fasting insulin (not always included in standard panels) provides earlier detection of insulin resistance than glucose or HbA1c alone.

Interventions for Each BMI Category

The 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (Jensen et al., Circulation, 2014) provides the evidence-based clinical framework for weight management by BMI category:

BMI 18.5–24.9 (Healthy Weight): The goal is maintenance, not weight loss. Focus on regular physical activity (150–300 minutes per week of moderate aerobic activity), mostly whole-food nutrition, adequate sleep (7–9 hours), and stress management. Routine clinical care including annual physical exams and age-appropriate cancer screenings.
BMI 25–29.9 (Overweight): Comprehensive lifestyle intervention is appropriate. This includes a structured calorie deficit (300–500 kcal/day), increased physical activity (target 200–300 minutes per week), and behavioral strategies. A 5–10% weight loss is the initial target. Request bloodwork (fasting glucose, lipids, BP) and measure waist circumference to establish baseline metabolic markers.
BMI 30–34.9 (Class I Obesity): Lifestyle intervention plus consideration of pharmacotherapy. The 2013 guidelines recommend pharmacotherapy for adults with BMI ≥ 30, or BMI ≥ 27 with one or more obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Medications available include orlistat (lipase inhibitor), phentermine-topiramate, liraglutide, and semaglutide.
BMI 35–39.9 (Class II Obesity): Intensive lifestyle and pharmacotherapy; specialist referral may be appropriate. The risk of developing at least one obesity-related comorbidity over 10 years is substantial. Concurrent management of any existing comorbidities (OSA, hypertension, diabetes) is essential.
BMI 40+ (Class III Severe Obesity): Comprehensive assessment for bariatric surgery. ASMBS 2022 guidelines recommend surgical evaluation for BMI ≥ 40, or BMI ≥ 35 with significant comorbidities. Roux-en-Y gastric bypass and sleeve gastrectomy are the two most common procedures with the strongest long-term outcome data.

Lifestyle Intervention: The Foundation

Regardless of BMI category, lifestyle modification is the foundation of any weight management strategy. The U.S. Preventive Services Task Force (JAMA, 2018) recommends behavioral weight loss interventions for all adults with BMI ≥ 30, and those with BMI ≥ 25 with comorbidities. Effective behavioral programs include:

Dietary modification: A sustainable caloric deficit of 300–500 kcal/day, with adequate protein (1.2–1.6 g/kg target body weight), forms the nutritional basis. The specific diet composition (low-carb, Mediterranean, low-fat) matters less than sustainability — any pattern that produces a consistent caloric deficit will produce weight loss.
Physical activity: 200–300 minutes per week of moderate-intensity activity ( brisk walking, cycling, swimming) for weight loss; 150 minutes per week for maintenance. Resistance training 2–3 times per week preserves fat-free mass during caloric restriction.
Behavioral strategies: Self-monitoring (weekly weigh-ins, food journals), stimulus control (removing high-calorie foods from the home environment), goal-setting, and problem-solving are the most evidence-based behavioral components of weight management programs.

When to Consider Medication or Surgery

Pharmacotherapy is appropriate when BMI is ≥ 30, or ≥ 27 with at least one obesity-related comorbidity, and lifestyle modification alone has not produced adequate results over 6 months. Current FDA-approved options with the strongest evidence:

Semaglutide (GLP-1 agonist): The SELECT trial (Novo Nordisk, 2023) demonstrated 20% body weight loss over 68 weeks and a 20% reduction in major adverse cardiovascular events in adults with BMI ≥ 27 and established cardiovascular disease. Administered as a weekly subcutaneous injection.
Tirzepatide (dual GIP/GLP-1 agonist): The most effective pharmacotherapy currently available, producing weight loss of up to 20–22% in clinical trials (SURMOUNT-1, NEJM). Mechanism combines GLP-1 receptor agonism with GIP receptor agonism for enhanced satiety signaling.
Liraglutide (GLP-1 agonist): Daily subcutaneous injection; approximately 6–8% body weight loss in trials. Also approved for diabetes management at a lower dose.

Important caveat: 20–40% of weight lost via GLP-1 agonists is lean mass, confirmed by serial DEXA measurements in clinical trials. Concurrent resistance training (2–3 sessions per week) and adequate protein intake (1.2–1.6 g/kg) are essential to minimize iatrogenic sarcopenia. These medications require medical supervision due to risks of GI distress, pancreatitis (rare but documented), and the need for dose titration.

Bariatric surgery (ASMBS 2022 Guidelines) is the most effective treatment for severe obesity with the strongest long-term outcome data. Roux-en-Y gastric bypass produces mean weight loss of approximately 30–35% of initial body weight maintained at 5–10 years. sleeve gastrectomy produces approximately 25–30% weight loss at 5 years. Both procedures produce metabolic remission (resolution of type 2 diabetes, hypertension, dyslipidemia) in the majority of patients — an effect that exceeds what can be explained by weight loss alone, likely mediated through changes in gut hormone signaling.

Resources and references

National Institutes of Health. Clinical Guidelines on Overweight and Obesity in Adults. NIH Publication 98-4083, 1998.
Jensen MD, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation, 2014.
U.S. Preventive Services Task Force. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality. JAMA, 2018.

From BMI to Action — Next Steps After Checking Your Score

Moving Beyond BMI: Secondary Health Screenings

Interventions for Each BMI Category

Lifestyle Intervention: The Foundation

When to Consider Medication or Surgery

Resources and references

Frequently asked questions

Keep exploring

BMI Categories Explained

How to Lower Your BMI Safely

Adult BMI Calculator